NASDAQ · NDRA
Healthcare · Medical - Diagnostics & Research
$5.60
Down-$0.20 (-3.57%)
Updated Sep 16, 2026, 3:11 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NDRA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NDRA.
NDRA research
Company profile and research snapshot.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
| Sep 22, 2025 | Ascendiant Capital | Buy | — |
| May 30, 2025 | Ascendiant Capital | Buy | — |
| Apr 21, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 2, 2026
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares increased
Benzinga · Aug 17, 2026
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.84) by 107.14 percent. This is a 103.51 percent increase over losses of $(1.71) per share
Benzinga · Jun 1, 2026
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.
Benzinga · May 18, 2026
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.14) by 4.39 percent. This is a 41.4 percent increase over losses of $(1.86) per share from
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NDRA.
